SELLAS Life Sciences (SLS) Operating Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Operating Expenses data on file, last reported at $9.3 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 52.6% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $31.5 million, a 12.65% increase from a year earlier, with the FY2025 full-year figure at $28.3 million, down 10.28% from the prior year.
• Operating Expenses for Q1 2026 stood at $9.3 million, up from $8.3 million in the prior quarter.
• Over the last five years, Operating Expenses for SLS reached as high as $17.7 million in Q1 2022 and fell as low as $6.1 million in Q1 2025.
• Historically, Operating Expenses has averaged $8.8 million across 5 years, with a median of $8.3 million in 2025.
• Across the five-year window, Operating Expenses jumped 123.22% in 2022 and sank 37.14% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $9.4 million in 2022, then declined by 13.43% to $8.2 million in 2023, then declined by 15.4% to $6.9 million in 2024, then advanced by 19.33% to $8.3 million in 2025, then climbed by 12.08% to $9.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $9.3 million in Q1 2026, $8.3 million in Q4 2025, and $7.1 million in Q3 2025.